altM raises $10.3 million to scale residue-based chemicals

altM has raised $10.3 million in a Series A funding round led by new investors Rainmatter by Zerodha and Mela Ventures. According to altM's funding announcement, the Bengaluru-based specialty chemicals startup also attracted existing investors Omnivore, Theia Ventures, Aureolis Ventures and Spectrum Impact, alongside VC Grid and strategic angel investors.

The new round is nearly three times the size of the $3.5 million seed financing altM raised in 2023. altM said it will use the proceeds to expand manufacturing capabilities, research and development, customer qualification programmes, and its engineering and commercial teams. The company will direct that spending toward its move from pilot-scale production to commercial manufacturing.

For altM, the Series A adds operating capacity at the point where promising molecules must become consistent industrial supply. The timing matters because altM is moving from a pilot plant toward commercial manufacturing while serving multiple end markets.

What does the funding change for altM and its buyers?

The Series A gives altM the capital to move from pilot-scale production toward commercial manufacturing. For buyers, it means greater capacity for qualification and deployment as altM tries to move products beyond pilot batches. altM still needs to translate six molecules at demonstration scale into three pilot-plant products and then dependable manufacturing output.

Founded in 2022 by former Tesla manufacturing leaders Apoorv Garg and Yugal Raj Jain, altM is developing a specialty chemicals platform that converts agricultural residue into high-performance industrial chemicals. Bioprocessing scientist Dr Harshad Velankar later joined as chief scientific officer.

The platform converts lignocellulosic biomass, including sugarcane bagasse and rice straw, into materials for beauty and personal care, textiles, industrial chemicals, construction, packaging and consumer goods. It uses cellulose, hemicellulose and lignin to produce multiple products from a single feedstock.

That design turns agricultural residue into a source of industrial carbon and reduces dependence on fossil-derived raw materials, according to altM. Since raising $3.5 million in a seed round in 2023, altM has built an integrated R&D and pilot manufacturing facility in Bengaluru.

The site brings laboratory research, demonstration manufacturing and pilot production under one roof. altM has expanded its laboratory footprint nearly fivefold and commissioned its demonstration manufacturing facility. Co-locating those stages matters because the Series A is funding manufacturing, customer qualification and commercial hiring at the same time.

altM has advanced six molecules to demonstration scale. It has selected three for pilot plant production. Half of the six-molecule demonstration set now has a defined next step at pilot scale, while the new capital supports more testing and deployment.

altM's first products moving toward commercialisation are:

• A lignin-derived SPF booster for suncare applications.
• A cellulose-based rheology modifier.
• Bio-derived ferulic acid for cosmetics and personal care formulations.

The announced slate tests whether altM can turn separate platform outputs into products with defined commercial applications. For customers, qualification and repeatable supply determine when a promising molecule becomes usable at industrial scale.

The Series A will also support customer qualification programmes and expansion of altM's engineering and commercial teams. That matters because altM must connect production capacity with customer qualification and commercial execution. The round links those functions in one expansion plan.

altM's funding announcement identifies Scimplifi, Covvalent, Atomgrid and Tulon Materials as competitors. Each has also raised fresh funding this year. That puts altM in a peer group where investors can compare both the underlying science and the pace of industrial scale-up.

For practitioners, the relevant comparison is how quickly each rival turns fresh capital into qualified, repeatable production. The competitive stakes are manufacturing scale, customer qualification and the pace of customer deployment.

The latest funding will help altM scale manufacturing operations and expand customer deployments as it seeks a broader platform for producing industrial chemicals from agricultural residue. For altM, the immediate task is converting that capital into repeatable output rather than simply enlarging its pilot footprint.

For altM, the next proof point is whether customer qualification and pilot production translate into repeatable commercial manufacturing. The $10.3 million expands its capacity and team, but the commercial test rests on converting three pilot-stage molecules into dependable supply. Success would validate its single-feedstock model across multiple products and markets.